Latest BioDelivery Sciences International Inc. Stories

RALEIGH, N.C., May 7, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch 2013 Health Care Conference. The presentation is scheduled for Tuesday, May 14, 2013 at 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time), at the Encore at Wynn in Las Vegas, Nevada. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Dr. Sirgo...

RALEIGH, N.C., April 29, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the appointment of Thomas W. D'Alonzo to the company's Board of Directors. Mr. D'Alonzo previously served on the BDSI Board of Directors from August 2006 through June 2008. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) "We are very pleased to once again have Tom D'Alonzo as a member of our Board of Directors," said Dr. Frank E. O'Donnell, Jr., Executive...

Completed Phase 2 study demonstrated efficacy in a pain condition with significant unmet need RALEIGH, N.C., March 26, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that it has entered into a worldwide licensing agreement with privately held Arcion Therapeutics (Arcion), where BDSI will develop and commercialize topical clonidine gel (formerly ARC4558) for the treatment of painful diabetic neuropathy (PDN) and potentially other...

NDA filing for BEMA Buprenorphine/Naloxone (BUNAVAIL) on track for mid-2013 RALEIGH, N.C., March 18, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2012 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's 2012 achievements and an update on business operations and upcoming milestones for 2013. (Logo:...

RALEIGH, N.C., March 13, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 25(th) Annual ROTH Conference. The presentation is scheduled for Monday, March 18, 2013 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time), at the Ritz Carlton, Laguna Nigel, California. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) Dr. Sirgo will focus on the...

RALEIGH, N.C., March 1, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Cowen and Company 33(rd) Annual Health Care Conference. The presentation is scheduled for Tuesday, March 5, 2013 at 10:40 a.m. Eastern Time, at The Boston Marriott Copley Place. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Dr. Sirgo will focus on the development...

RALEIGH, N.C., Feb. 27, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that the Company will host "Treatment of Pain and Opioid Dependence with Buprenorphine" for investors and analysts on Thursday, March 7, 2013 at 12:00 pm, in New York City. This event will include insightful discussion from medical experts with extensive experience in the management of chronic pain and opioid dependence using various formulations of buprenorphine,...

RALEIGH, N.C., Feb. 5, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 15(th) Annual BIO CEO and Investor Conference. The presentation is scheduled for Tuesday, February 12, 2013 at 1:30 p.m. Eastern Time, at The Waldorf Astoria in New York City. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Dr. Sirgo will focus on the development...

RALEIGH, N.C., Jan. 22, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the completion of its study evaluating the safety and tolerability of BEMA Buprenorphine/Naloxone (BNX) in the treatment of opioid dependent patients. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) "We are pleased with the outcome of this study," stated Dr. Andrew Finn, Executive Vice President of Product Development for BDSI. "Results...

RALEIGH, N.C., Dec. 17, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the hiring of George K. Ng as Senior Vice President & General Counsel. In this capacity, Mr. Ng will be responsible for overseeing BDSI's legal, compliance and intellectual property activities. Mr. Ng will report directly to Dr. Mark A. Sirgo, President and Chief Executive Officer. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Mr. Ng has more...